Brainstorm Shares the Results of its Phase 3 Study of NurOwn to Treat ALS
source: pixabay.com

Brainstorm Shares the Results of its Phase 3 Study of NurOwn to Treat ALS

  According to a report in BioPharma Dive, Brainstorm Therapeutics, a New York biotechnology company, said that while its NurOwn therapy for amyotrophic lateral sclerosis (ALS) appeared to have a…

Continue Reading Brainstorm Shares the Results of its Phase 3 Study of NurOwn to Treat ALS